Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 17/20 | 0.61 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746766 | 0.85 | S1PR1 (0.45) | S1PR1S1PR3 | |
| SCHEMBL1856300 | 0.80 | S1PR1 (0.58) | S1PR1S1PR3 | |
| SCHEMBL1861990 | 0.79 | S1PR1 (0.55) | S1PR1S1PR3S1PR5GABRG2GABRB3 | |
| SCHEMBL2747009 | 0.78 | S1PR1 (0.47) | S1PR1S1PR3 | |
| SCHEMBL1862109 | 0.78 | S1PR1 (0.76) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2747311 | 0.74 | S1PR1 (0.44) | S1PR1S1PR3 | |
| SCHEMBL1859650 | 0.74 | S1PR1 (0.63) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1859310 | 0.73 | S1PR1 (0.93) | S1PR1S1PR3 | |
| SCHEMBL2747674 | 0.73 | S1PR1 (0.63) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1424804 | 0.72 | S1PR1 (0.50) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697732-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-04-15 | — | — | US | claimed |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-02 | — | — | US | claimed |
| EP-1979345-B1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-04 | — | — | EP | claimed |
| US-20090005421-A1 | Novel Pyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | claimed |
| EP-1979345-A2 | NOVEL PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-15 | — | — | EP | claimed |
| WO-2007086001-A2 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | claimed |
| US-8697732-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-02 | — | — | US | disclosed |
| US-8178562-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-05-15 | — | — | US | disclosed |
| EP-1979345-B1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-20090005421-A1 | Novel Pyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1979345-A2 | NOVEL PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007086001-A2 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005421-A1 | Novel Pyridine Derivatives | NFATC1, TPMT, CD47 | S1PR1 1245/4885S1PR3 1086/4885S1PR5 1144/4885 |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | NFATC1, TPMT, CD47 | S1PR1 1245/4885S1PR3 1086/4885S1PR5 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.